List your tool

Head to head · 2026

Artera vs Proscia

Pricing, free plans, ratings, features, pros and cons, side by side. Where one comes out ahead, we mark it.

Artera

FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions

4.4Not listed

Visit Artera (opens Artera in a new tab)

Proscia

FDA-cleared digital pathology platform for primary diagnosis and biomarker research

4.3Not listed

Visit Proscia (opens Proscia in a new tab)

Who comes out ahead

Based only on the facts in our directory. The right pick still depends on the job you need done.

  • Lower starting price

    Not comparable

    Not comparable: Artera does not list a price

  • Free plan

    Tie

    Neither has one

  • Higher rating

    Artera

    4.4 against 4.3

  • Same job?

    Yes

    Both are Healthcare AI tools

Side by side

Compared onArteraProscia
Our rating4.4Better4.3
Starts atNot listedNot listed
Free planNoNo
CategoryHealthcare AIHealthcare AI
PlansSee pricingSee pricing
Key features
  • Multimodal AI trained on digitized biopsy images paired with clinical data
  • FDA De Novo authorization for the ArteraAI Prostate Test
  • FDA clearance for ArteraAI Breast digital pathology risk stratification
  • Results delivered in as little as two days after sample submission
  • Inclusion in National Comprehensive Cancer Network (NCCN) treatment guidelines
  • FDA-cleared for primary clinical diagnosis in AP-Dx
  • Concentriq AP, AP-Dx and LS configurations
  • Biomarker research and clinical trial workflows
  • Cloud deployment
  • Predetermined Change Control Plan for regulatory compliance
Pros
  • Regulatory clearance (FDA De Novo, NCCN guideline inclusion) beyond most AI health startups
  • Published clinical evidence showing improved outcome prediction versus existing risk models
  • Adopted by a meaningful share of US prostate cancer clinicians already
  • FDA clearance for primary diagnosis, not just research viewing
  • Deployed across 4,000 hospitals and 16 of the top 20 pharma companies
  • Rated highest in KLAS 2026 in both the US and Europe
Cons
  • Not a self-serve software product; access runs through labs, clinicians, and insurance billing
  • Pricing is not public and varies by payer and region
  • Limited to prostate and breast cancer currently, not a general oncology platform
  • No published pricing
  • Requires compatible scanning hardware
  • Adoption is a laboratory-wide programme, not a purchase
CompanyArtera, founded 2021Proscia Inc.

Prices come from each vendor's pricing page, last checked 20260814. Check the vendor before you buy.

FAQ

Questions people ask

Is Artera better than Proscia?

In our reviews Artera scores 4.4 and Proscia scores 4.3. The better pick depends on the job. Artera: FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions. Proscia: FDA-cleared digital pathology platform for primary diagnosis and biomarker research.

Which is cheaper, Artera or Proscia?

Artera: see pricing. Proscia: see pricing.

Do Artera and Proscia have free plans?

Neither lists a free plan.

More comparisons

Artera compared with

All Artera alternatives

Proscia compared with

All Proscia alternatives